An interventional study of Sleep Behavioral Intervention and Standard Obesity Treatment in Obesity and Overweight and Sleep Disorder, sponsored by University of Beira Interior. Recruiting at 2 sites in Portugal. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by University of Beira Interior · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Obesity with a site in Portugal — 26 open to participants now, 32 under way, 12 of them phase 3. Obesity · Portugal.
Among the 68 studies in Obesity with a site in Portugal, this one is the 35th largest by planned enrollment of the 62 interventional ones that give a count, is one of 10 that started in 2025, is one of 35 with no phase, reaches primary completion later than 11 of the 31 other live ones, and was the 53rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →26 of the 68 studies in Obesity with a site in Portugal are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Portugal, United States, Belgium and 7 more countries
Ages 6–11
Novo Nordisk A/S · Sites in Portugal, United States, Greece and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in Portugal, United States, Argentina and 16 more countries
Ages 18+
Hospital de Sao Sebastiao · Sites in Portugal
Ages 18+ · Women only
Novo Nordisk A/S · Sites in Portugal, United States, Australia and 23 more countries
Ages 8–18
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 23 · Phase 4 1
First in 2002; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 150 across the 62 interventional studies, 4,103 across the 6 observational. Of the 27 that completed or were terminated, 7 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 68 have an industry lead sponsor. The 10 most frequent:
University of Beira Interior is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
University of Beira Interior has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity with a site in Portugal that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT06771024Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do AlgarvCommunity Physical Exercise Program in Chronic Disease | 2026-12 |
| NCT07289529University of CoimbraCOMPASS 65+ - Community-based Physical Activity Snacks for Healthy Aging in Overweight and Obese Aged Adults | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 68 studies in Obesity with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sleep plays a crucial role in energy balance, alongside diet and physical activity. Research has linked poor sleep quality and short sleep duration to obesity and cardiometabolic risk, such as insulin resistance and hypertension. The nature of this association is complex, and several mechanims have been suggested.
Scientific evidence suggests that sleep interventions may provide additional benefits in optimizing the effectiveness of overweight/obesity treatment in pediatric populations. Although some studies have explored this hypothesis, methodological heterogeneity hampers clear interpretation of the results.
The main goal of this clinical trial is is to evaluate the efficacy of a sleep behavioral intervention, combined with standard obesity treatment, in reducing adiposity (measured by BMI z-score, fat mass percentage, or fat-free mass index) in adolescents with overweight or obesity.
This randomized controlled trial will compare a control group receiving treatment as usual (or standard obesity treatment) with an intervention group receiving treatment as usual plus a sleep behavioral intervention.
Participants will be randomized into two groups: intervention and control. Throughout the study period, all medical consultations will include standard interventions focused on nutrition, physical activity/sedentary behavior, and other lifestyle factors. The sleep-focused intervention will be delivered by psychologists.
Participants will attend clinic visits every two months during the 6-month intervention period, and every three months during the subsequent 6-month follow-up period.
A randomized controlled trial (open-label, behavioral intervention) will be conducted at ULS Cova da Beira and Hospital CUF Porto, enrolling 126 adolescents (ages 13-17) diagnosed with overweight or obesity and poor sleep quality. Participants will be randomized into two groups: the intervention group (sleep behavioral intervention plus treatment as usual) and the control group (treatment as usual).
In addition to the primary aim, the researchers will evaluate several secondary outcomes, including the efficacy of the intervention in relation to: cardiometabolic risk, sleep patterns, eating patterns, physical activity level, emotional well-being/self-compassion, quality of life, leptin and ghrelin levels, and tryptophan and melatonin metabolism.
Throughout the study period, all medical consultations will include standard multicomponent behavioral intervention. The sleep behavioral intervention will be conducted by psychologists.
The intervention consists of seven cognitive-behavioral therapy (CBT) sessions over six months, focusing on sleep hygiene, self-monitoring, stimulus control, cognitive therapy, and relaxation techniques.
Data collection and analysis will include objective sleep assessment using actigraphy and a level 3 ambulatory sleep study. Blood samples will be collected at baseline, six months, and twelve months to analyze metabolic markers. From the samples collected at months 0 and 6, a portion will be appropriately stored for additional analysis at an external facility to quantify leptin, ghrelin, and tryptophan pathway metabolites.
Anthropometric and clinical assessments will include measurements of body mass index (BMI), waist circumference, body composition, and blood pressure. Validated questionnaires will be used to evaluate sleep patterns, eating behaviors, physical activity, quality of life, emotional well-being, and self-compassion.
It is anticipated that the sleep behavioral intervention combined with standard treatment will be more effective than standard treatment alone not only in reducing adiposity, but also in improving cardiometabolic risk, sleep patterns, eating patterns, physical activity, emotional well-being, self-compassion, and in regulating hormonal and metabolic pathways including ghrelin, leptin, and the tryptophan-melatonin axis, as outlined in the study hypotheses
The study also aims to clarify the role of ghrelin and leptin levels, as well as the tryptophan pathway, in the interaction between sleep and obesity and in the effects of the intervention
Emotional well-being and self-compassion are expected to mediate the response to obesity intervention and the sleep-obesity relationship, potentially influencing or influenced by the tryptophan metabolic pathway, particularly serotonin levels.
By deepening the knowledge about the relationship between sleep and obesity, this research may contribute to optimize interventions for pediatric obesity, which would have an unequivocal positive impact.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard interventions focused on nutrition, physical activity/sedentary behavior, and other lifestyle aspects.
Other: Standard Obesity Treatment
Standard intervention plus sleep-focused intervention. The sleep intervention will be conducted by psychologists. These monthly sessions, delivered in person or via video call, will be scheduled on the same day as the medical consultation whenever possible. The session planning and objectives are outlined in the study protocol.
Behavioral: Sleep Behavioral Intervention · Other: Standard Obesity Treatment
Our research team, composed by pediatricians with experience in Obesity and Adolescent Medicine, and clinical psychologists with experience in Sleep, Obesity, and Cognitive Behavioral Therapy (CBT), developed a specific manual for this project: "Behavioral Sleep Intervention - SLEEP-OB - Therapist Support Manual." The manual was adapted based on CBT models for adults and adolescents with insomnia and on CBT for adolescents with other sleep disorders and comorbidities, namely obesity. The behavioral intervention aims to promote sustainable changes in sleep. It includes behavioral strategies (such as sleep restriction, stimulus control), cognitive strategies (cognitive reappraisal/restructuring, cognitive control, paradoxical intention), mixed strategies (sleep education/hygiene, relaxation), self-monitoring, and problem identification and resolution. The intervention will take place over six months, with a total of seven sessions (in-person and by video call).
Also known as: Sleep intervention, Cognitive Behavioral Therapy for sleep disorders
Standard obesity treatment for pediatric obesity according to international guidelines. It comprises pediatric appointments, and usually also nutrition and nursing appointments, every 2 to 3 months. These appointments include an anthropometric evaluation, physical examination and personalized multicomponent behavioral intervention with focus on nutrition, physical activity/sedentary behavior and other lifestyle recommendations. This standard intervention is common for both groups/arms.
Also known as: treatment as usual
BMI z-score at 6 months
Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2. Then, BMI z-score will be calculated by WHO Anthroplus software 3.2.2.
Time frame: 6 months
BMI at 6 months
Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2.
Time frame: 6 months
Fat mass percentage at 6 months
Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). Fat mass percentage (%FM) assessed using bioelectrical impedance analysis with InBody 270®.
Time frame: 6 months
Fat-free mass index at 6 months
Variation between Visit 1 (baseline) and Visit 4 (end of the intervention). FFMI (kg/ m2) calculated using FFM (in kilograms) and height (in meters).
Time frame: 6 months
Participants achieving a BMI reduction ≥5%
Percentage of participants achieving a BMI reduction ≥5% between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Participants achieving a BMI reduction ≥10%
Percentage of participants achieving a BMI reduction ≥10% between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in Waist circumference centile
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. waist circumference in centimeters, and centiles according to Sharma AK, et al. Pediatr Res. 2015.
Time frame: 6 months and 12 months
Fat mass percentage at 12 months
Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Fat mass percentage (%FM) assessed using bioelectrical impedance analysis with InBody 270®.
Time frame: 12 months
Fat-free mass index at 12 months
Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). FFMI (kg/ m2) calculated using FFM (in kilograms) and height (in meters).
Time frame: 12 months
BMI z-score at 12 months
Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2. Then, BMI z-score will be calculated by WHO Anthroplus software 3.2.2.
Time frame: 12 months
BMI at 12 months
Variation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2.
Time frame: 12 months
Change in Waist-to-height Ratio
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in C-reactive protein
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in Fasting Lipid: Total Cholesterol
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in Fasting Lipid: LDL-cholesterol
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in Fasting Lipid: HDL-cholesterol
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in Fasting Lipid: Triglycerides
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in centiles of Systolic and Diastolic Blood Pressure
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. Blood pressure measured and centiles according to the American Academy of Pediatrics.
Time frame: 6 months and 12 months
Change in HbA1c
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Time frame: 6 months and 12 months
Change in Glycaemic Category
Variation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes (T2DM)" 2 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: fasting plasma glucose (FPG) \<100 mg/dL and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes (T2DM): FPG ≥126 mg/dL and/or HbA1c ≥6.5%
Time frame: 6 months and 12 months
Change in HOMA-B
Variation between Visit 1 and Visit 4 and between Visit and Visit 6. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).
Time frame: 6 months and 12 months
Change in HOMA-IR
Variation between Visit 1 and Visit 4 and between Visit and Visit 6. HOMA-IR was calculated as: Insulin resistance (%) = fasting insulin \[mU/L\] x FPG \[mmol/L\]/ 22.5. R
Time frame: 6 months and 12 months
Change in Continuous metabolic syndrome score
Variation between Visit 1 and Visit 4 and between Visit and Visit 6. Calculation according to Vukovic R, et al. PLoS One. 2017 Dec 6;12(12):e0189232.
Time frame: 6 months and 12 months
Change in Sleep quality
Sleep quality assessed by the Pittsburgh Sleep Quality Index, at Visit 1and Visit 4, and at Visit 6.
Time frame: 6 months and 12 months
Change in sleep quality - actigrafy
Sleep quality assessed by actigraphy and sleep diary, at Visit 1and Visit 4.
Time frame: 6 months
Change in Respiratory Sleep disorder
Respiratory sleep disorder assessed by the Pediatric sleep questionnaire at Visit 1and Visit 4.
Time frame: 6 months
Change in Diet Quality
Mediterranean Diet Quality assessed with KIDMED questionnaire, at Visit 1 and Visit 4.
Time frame: 6 months
Change in Eating behavior
MEating behavior assessed with Eating Attitudes Test questionnaire, at Visit 1 and Visit 4.
Time frame: 6 months
Change in emotional well-being
At Visit 1 and Visit 4: Emotional well-being assessed through the WHO-5.
Time frame: 6 months
Change in Quality of life
At Visit 1 and Visit 4: Quality of life evaluated with the KIDSCREEN 52 questionnaire.
Time frame: 6 months
Change in self-compassion
At Visit 1 and Visit 4: Self-compassion evaluated with the Self-Compassion Scale for adolescents.
Time frame: 6 months
Change in Physical activity
Physical activity assessed with International Physical Activity Questionnaire for Adolescents, at Visit 1 and Visit 4.
Time frame: 6 months
Change in Physical activity - actigraphy
Physical activity assessed by actigraphy, at Visit 1 and Visit 4.
Time frame: 6 months
Tryptophan pathway metabolites measurement
Levels of tryptophan, kynurenine, serotonin, and melatonin in plasma samples, by metabolomic analysis/ liquid chromatography, at baseline (Visit 1) and after the Intervention (Visit 4).
Time frame: 6 months
Leptin and ghrelin levels
Levels of leptin and ghrelin will be measured in plasma samples using enzyme-linked immunosorbent assay (ELISA) at baseline (Visit 1) and after the intervention (Visit 4).
Time frame: 6 months
Plan to share: Yes — Individual participant data may be shared upon request, provided that all identifying information is removed to safeguard participant anonymity. This process upholds the confidentiality and privacy of participants, fully complying with ethical and legal standards for data protection.
Supporting information: Study protocol, Statistical analysis plan
Time frame: June 2026 to June 2027
Access criteria: The data supporting the findings of this study will be available upon request from the corresponding author. Each request will be reviewed by the research team and the Ethics Committees that approved the study to ensure compliance with ethical standards.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Beira Interior